NASDAQ:NTRP Neurotrope (NTRP) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free NTRP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.71▼$2.9350-Day Range$0.92▼$1.0552-Week Range$0.68▼$3.85Volume1,453 shsAverage Volume12,840 shsMarket Capitalization$2.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsEarningsSocial MediaStock AnalysisCompetitorsEarningsSocial Media Get Neurotrope alerts: Email Address Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> About Neurotrope Stock (NASDAQ:NTRP)Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.Read More Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> NTRP Stock News HeadlinesApril 4, 2024 | morningstar.comNextTrip Inc NTRPAugust 17, 2023 | finance.yahoo.comAlzheimer's Disease Market Predicted to Surge at a CAGR of 20% During the Study Period (2019–2032), Assesses DelveInsightApril 23, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...June 22, 2022 | finance.yahoo.comAt 6.9% CAGR, Global Erectile Dysfunction Drugs Market Size & Share Will Hit US$ 5.94 Billion | Industry Trends, Demand, Growth, Value, Analysis & Forecast Report by Zion Market Research - Yahoo FinanceApril 7, 2022 | prnewswire.comVascular Dementia Market Is Contemplated to Surge at a CAGR of 4.05% in the 7MM for the Study Period of 2019-2032, Estimates DelveInsight - PR NewswireMarch 9, 2022 | radio.foxnews.comDr. Nicole Saphier On New Study That Finds Covid May Cause Changes In The Brain - FOX News RadioDecember 7, 2021 | seekingalpha.comPetros Pharmaceuticals: Advancing Complementary Men's Health Therapeutics - Seeking AlphaNovember 16, 2021 | marketscreener.comPETROS PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q) - marketscreener.comApril 23, 2024 | WealthPress (Ad)The system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.August 10, 2021 | nasdaq.comNeurotrope, Inc. Common Stock (NTRP)August 5, 2021 | prnewswire.comPrimary Hyperoxaluria Market Size Growth to Shore Up at a Substantial CAGR of 40.40% During the Study Period 2018-30 in the 7MM | DelveInsight - PRNewswireSee More Headlines Receive NTRP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurotrope and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/30/2018Today4/23/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorConsumer Discretionary Industry Miscellaneous manufacturing industries Sub-IndustryN/A Current SymbolNASDAQ:NTRP CUSIPN/A CIK1513856 Webwww.neurotropebioscience.com Phone973-242-0005Fax505-424-3174Employees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($10.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,690,000.00 Net Margins-1,123.90% Pretax Margin-1,123.90% Return on Equity-180.93% Return on Assets-148.77% Debt Debt-to-Equity RatioN/A Current Ratio1.65 Quick Ratio0.76 Sales & Book Value Annual Sales$630,000.00 Price / Sales3.63 Cash FlowN/A Price / Cash FlowN/A Book Value$9.67 per share Price / Book0.30Miscellaneous Outstanding Shares780,000Free Float679,000Market Cap$2.29 million OptionableNo Data Beta1.54 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Charles S. Ryan J.D. (Age 56)Ph.D., Chief Exec. Officer and Director Comp: $850.21kDr. Daniel L. Alkon (Age 78)Pres & Chief Science Officer Comp: $275kMr. Robert Weinstein (Age 60)Chief Financial Officer, Exec. VP, Sec. and Treasurer Comp: $423.82kMr. Jeffrey BenisonDirector of Corp. CommunicationsDr. Alan J. Tuchman (Age 73)Acting Chief Medical Officer Key CompetitorsHempaccoNASDAQ:HPCOChina Liberal EducationNASDAQ:CLEUSafe & GreenNASDAQ:SGBXiMedia BrandsNASDAQ:IMBISinging MachineNASDAQ:MICSView All Competitors NTRP Stock Analysis - Frequently Asked Questions When is Neurotrope's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our NTRP earnings forecast. How were Neurotrope's earnings last quarter? Neurotrope, Inc. (NASDAQ:NTRP) announced its earnings results on Tuesday, October, 30th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.05. Neurotrope had a negative net margin of 1,123.90% and a negative trailing twelve-month return on equity of 180.93%. What other stocks do shareholders of Neurotrope own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neurotrope investors own include Sarepta Therapeutics (SRPT), Neos Therapeutics (NEOS), Fibrocell Science (FCSC), Alibaba Group (BABA), Zevra Therapeutics (KMPH), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Vistagen Therapeutics (VTGN), Intel (INTC). This page (NASDAQ:NTRP) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsIncredible Opportunity to Retire FAST!Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurotrope, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
